Faculty & Staff at TUC

Denene Lofland

Denene Lofland

College: COM

Department: Basic Sciences

Title: Associate Professor

Phone: (707) 638-5962

Fax: (707) 638-5255

E-Mail: denene.lofland@tu.edu

Office: Administration & Faculty 1, Rm. 229

Dr. Denene Lofland received a Ph.D. in Pathology, with an emphasis in microbiology, from Virginia Commonwealth University School of Medicine. As a former biotech company director, Dr. Lofland managed successful clinical projects that resulted in regulatory filings of four compounds and FDA approval for two new antimicrobial drugs for the treatment of pneumonia and cystic fibrosis. She also supervised several projects, including government-sponsored research which required her to maintain a secret security clearance. Her areas of expertise include medical microbiology, bioterrorism, and new drug discovery for pre-clinical anti-infective drug candidates and drug development through Phase III clinical trials. She has published numerous articles in a variety of scientific journals and contributed to the thirteenth edition of Bailey and Scott’s Diagnostic Microbiology.

Institution                                     Degree                        Field of Study

Virginia Commonwealth University     Ph.D.                           Pathology

Virginia Commonwealth University     M.S.                             Clinical Laboratory Science

Virginia Commonwealth University     BS summa cum laude    Medical Technology

 

Evaluation of Novel Molecules as Potential Antimicrobial Agents

The World Economic Forum recently concluded that “arguably the greatest risk . . . to human health comes in the form of antibiotic-resistant bacteria”. Historically the demand for new antibiotics was met by pharmaceutical companies.  However company-supported research has steadily declined. One solution is to move research into academia. The goal of my laboratory is to discover new antibacterial agents. This is done by performing in vitro experiments to predict the likelihood that a particular molecule will be effective in stopping the growth of infecting bacteria.

Evaluation of Novel Compounds as Potential Antimicrobial Agents. Principle Investigator, College of Osteopathic Medicine, Touro University, CA. $3,000.00.

Organic Compounds from Spanish Moss (Tillandsia usneoides) as Potential Green Antimicrobial Agents. Principle Investigator. Armstrong State University. $2,000.00.

Design and Synthesis of Small Molecule Chalcone and Curcumin Analogs as Anti-Cancer and Anti-Bacterial Therapeutics. Collaborator. Armstrong State University. $2,000.00.

JOURNALS

Bates C., and Lofland D., New Direct-Acting Antivirals for the Treatment of Hepatitis C. California DO. 2016. 16:2; 11-12.

Grossman T., Murphy T., Slee A., Lofland D., and J. Sutcliffe. Eravacycline (TP-434) is Efficacious in Animal Models of Infection. Antimicrobial Agents and Chemotherapy. 2015. 59:5, 2567-71.

Lofland D.
, Pera A., and T. Hendriksz. Update in the Diagnosis and Management of Central Nervous System Infections. California DO. 2014 14:3, 10-14.

Lofland D
., Josephat F., and A. Kogut. Cryptococcus gattii Expands its Territory. Medical Laboratory Observer. 2014. 46:7, 16-8.

Lofland D., Josephat F., and S. Partin. Fecal Transplant for Recurrent Clostridium difficile Infection. Clinical Laboratory Science. 2013. 26:3, 131-5.

Josephat F., Lofland D., and K. Jackson. Damaging Diarrhea: Acute Renal Failure Secondary to Intra-Abdominal Infection in an HIV-Positive Patient. Medical Laboratory Observer. 2012. 44:10, 46-50.

Card L., and D. Lofland. Candidal Endocarditis Presenting with Bilateral Lower Limb Ischemia. Clinical Laboratory Science. 2012. 25:3, 130-134.

Moralez E.I. and D. Lofland. Shigellosis with Resultant Septic Shock and Renal Failure. Clinical Laboratory Science. 2011. 24:3, 147-52.

Sun C., Hunt D.K., Clark R.B., Lofland D., O’Brien W.J., Plamondon L., and X. Xiao. Synthesis and Antibacterial Activity of Pentacyclines: A Novel Class of Tetracycline Analogs. Journal of Medicinal Chemistry. 2011. 54, 3704-31.

Clark R.B., Minsheng H., Fyfe C., Lofland D., O’Brien W.J., Plamondon L., Sutcliffe J.A., and X. Xiao. 8-Azatetracyclines: Synthesis and Evaluation of a Novel Class of Tetracycline Antibacterial Agents. Journal of Medicinal Chemistry. 2011. 54, 1511-28.

White A.R., BSAC Working Parties on Resistance Surveillance. The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: A Successful Collaborative Model. Journal of Antimicrobial Chemotherapy. 2008. 62 Suppl 2:ii3-14.

Griffith D. C., Corcoran E., Lofland D., Lee A., Cho D., Lomovskaya O., and M. N. Dudley.Pharmacodynamics of Levofloxacin against Pseudomonas aeruginosa with Reduced Susceptibility Due to Different Efflux Pumps: Do Elevated MICs Always Predict Reduced In Vivo Efficacy? Antimicrobial Agents and Chemotherapy. 2006. 50:1628-32.

Johnson K. W., Lofland D., and H. E. Moser. PDF Inhibitors: An Emerging Class of Antibacterial Drug Candidates. Current Drug Targets-Infectious Disorders. 2005. 5:39-52.

Ramanathan-Girish, S., McColm, J.,  Clements, J. Taupin, P.,Barrowcliffe, S., Hevizi, J., Safrin S., Moore, C., Patou, G., Moser, H., Gadd, A., Hoch, U., Jiang, V., Lofland, D., and K. W. Johnson. Pharmacokinetics in Animals and Man of a First-In-Class Peptide Deformylase Inhibitor. Antimicrobial Agents and Chemotherapy. 2004. 48:4835-42.

Lofland, D., Difuntorum, S., Waller, A., Clements, J., Weaver M., Karlowski, J., and K. Johnson. In Vitro Antibacterial Activity of the Peptide Deformylase Inhibitor BB-83698. Journal of Antimicrobial Chemotherapy. 2004. 53:664-8.

Gross M., Clements J., Beckett R.P., Thomas W., TaylorS., Lofland D., Ramanathan-Girish S., Garcia M., Difuntorum S.,Hoch U., Chen H., and K.W. Johnson. Oral Anti-Pneumococcal Activity and Pharmacokinetic Profiling of a Novel PDF Inhibitor. Journal of Antimicrobial Chemotherapy. 2004. 53:487-93.

Hu W., Burli R., Kaizerman J., Johnson K., Gross M., Iwamoto M., Jones, P., Lofland D., Difuntorum S., Chen H., Bozdogan B., Appelbaumn P., and H. Moser. DNA Binding Ligands with Improved In Vitro and In Vivo Potency against Drug-Resistant Staphylococcus aureus. Journal of Medicinal Chemistry. 2004: 47:4352-5.

Hu, X., Nguyen K., Jiang V., Lofland, D., Moser, H., and D. Pei. Macrocyclic Inhibitors for Peptide Deformylase: An SAR Study of the Ring Size. Journal of Medicinal Chemistry. 2004: 47:4941-4949.

Ferreira-Gonzalez, A., Fisher, L.M., Lehman, C.M., Langley, M.H., Lofland, D.H., Xia, Q., Nguyen, N.X., Modesto, D., Willoughby, J.B., Wilkinson, D.S., and C.T. Garrett. Detection of a Common Mutation in Factor V Gene Responsible for Resistance to Activated Protein C Causing Predisposition to Thrombosis. Journal of Clinical Laboratory Analysis. 1997; 11:328-335.

Gonzalez, A., Shiffman, M., Lofland, D., Langley, M., Gainey, D., and C. Garrett. Assessing Clinical Utility of Hepatitis C Virus Quantitative RT-PCR Data - Implications for Identification of Responders Among a-Interferon Treated Patients. Molecular Diagnosis. 1996; 1:109-120.

 

ABSTRACTS AND POSTERS

Lofland D., Josephat F., Bates C., and J. Gillespie.West Nile Virus in a Liver Transplant Patient. American Society for Clinical Laboratory Science. 2013.

Lofland D., Josephat F., Bates C., and J. Schachter. Drug Induced Immune Hemolytic Anemia Case Study. American Society for Clinical Laboratory Science. 2013.

Turner J., Harry K, Lofland D., and K. Madhusudhan. Characterization of the Absorption and Release Properties of Various Clinical Swab Types. Clinical Virology Symposium. 2010.

Lofland D., O’Brien W., Xiao X., Hunt D., Clark R., and L. Plamondon. Oral Antibacterial Activity of a Novel Pentacycline. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009.

Lofland D., O’Brien W., Xiao X., Clark R., He M., and L. Plamondon. In Vitro and In Vivo Activity of a Novel Broad-Spectrum 8-Aza Tetracycline. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009.

Xiao, X., Clark, R., He, M., Lofland, D., O’Brien, W., and L. Plamondon. Synthesis and Antibacterial Activities of Aza Tetracyclines: A Novel Class of Tetracycline Analogs. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009.

Xiao, X., Sun, C., Hunt, D., Clark, R., Lofland, D., O’Brien, W., and L. Plamondon. Synthesis and Antibacterial Activities of Pentacyclines: A Novel Class of Tetracycline Analogs. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009.

Burns, J., Stapp, J., Lofland D., AI Phase II Study Group. Microbiological Response in a Phase 2 Study of Azteonam Lysinate for Inhalation (AI) in Cystic Fibrosis (CF). Wright State University Research Symposium. 2006.

Burns, J., Stapp, J., Lofland D., AI Phase II Study Group. Microbiology results from a phase 2 clinical study of aztreonam lysinate for inhalation (AI): a new inhaled antibiotic to treat CF patients with Pseudomonas aeruginosa (PA). European Cystic Fibrosis Society, 2005.

Burns, J., Stapp, J., Lofland D., AI Phase II Study Group. Microbiological Response in a Phase 2 Study of Azteonam Lysinate for Inhalation (AI) in Cystic Fibrosis (CF). Interscience Conference on Antimicrobial Agents and Chemotherapy. 2005.

Lofland, D., Difuntorum, S., Waller, A., Clements, J., and K. Johnson. Antibacterial Spectrum, Bactericidal Activity, and Susceptibility Testing of the Peptide Deformylase Inhibitor GBB-83698. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003.

Difuntorum S., Johnson K., Gross M., Garcia M., Tanaka R., Hoch U., Ramanathan-Girish S., Kaizerman J., Duan J., Bürli R., Moser H., and D. Lofland. Anti-pneumococcal Activity of GSQ 7302, an Orally Efficacious Small Molecule Anti-genomic Therapeutic (SMAT). Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003.

Johnson K., Lofland D., Taylor S., Burli R., Gross M., Ayscough A., Moser H., Waller A., East S., Keavey K., Hu W., Hoch U., Girish S., Difuntorum S., Chen H., Garcia M., and J. Clements. Second Generation PDF Inhibitors for Respiratory Tract Infections. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003.

Ramanathan-Girish S., Johnson K., Lofland D., et al. Development of GSQ7302, A Small Molecule Anti-Genomic Therapeutic (SMAT) for Biodefense. Defense Advanced Research Projects Agency Internal Meeting. 2003.

Griffith D., Lofland D., Blais J., Rodriguez D, Park C., and M. Dudley. Pharmacodynamics of RWJ-54428 (MC-02,479) against Streptococcus pneumoniae. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2002.

Lee A., Lofland D., Madsen D., Warren M., Plesiat P., and O. Lomovskaya. Efflux Pump Inhibitors Enhance the Activity of Aminoglycosides in Pseudomonas aeruginosa. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2002.

Griffith D., M. Warren, D. Lofland, D. Cho, O. Lomovskaya, and M. Dudley. Method of Inoculum Preparation Effects MexAB-OprM Mediated Efflux on Levofloxacin Activity Against Pseudomonas aeruginosa In Vitro and In Vivo. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2001.

Mao W., A. Lee, M. Warren, K. Hoshino, Y. Ishida, D. Lofland, D. Cho. J, Blais, M. Dudley, and O. Lomovskaya. Use of Pump-Selective Inhibitors to Discriminate Between the Specific Mechanisms of Efflux-Mediated Levofloxacin Resistance in Pseudomonas aeruginosa. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2001.

Cho D., Lofland D.,Blais J., Tangen K., Cotter D., Lomovskaya O., Chamberland S., and M. N. Dudley. An Efflux Pump Inhibitor, MC-04,124, Enhances the Activity of Macrolides Against Gram Negative Bacteria. Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract F-1497. 2000.

Lofland, Denene and Lisa A. Weymouth. Erythromycin Resistance in Viridans Streptococci. American Society for Microbiology General Meeting, Abstract A-76. 1999.

Lofland, Denene and Lisa A. Weymouth. Multi-drug Resistance in Clinical Isolates of Viridans Streptococci. American Society for Microbiologist General Meeting, Abstract V-82. 1998.


BOOK CHAPTERS

Forbes BA, Sahm DF, Weissfeld AS. Bailey and Scott’s Diagnostic Microbiology. 13th edition. St. Louis: Mosby, Chpt 11 Evaluation of Antimicrobial Activity, Chpt 12 Laboratory Methods and Strategies for Antimicrobial Testing, Chpt 16 Non-Branching, Catalase-Positive, Gram-Positive Bacilli, Chpt 80 Sentinel Laboratory Response to Bioterrorism.



American Society for Microbiology

American Society for Clinical Pathology

American Society for Clinical Laboratory Science

Last Updated: 5/5/17